Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis

doi:10.1111/j.1365-2036.2004.02188.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Systems Maintenance, Monday, 15th February 2010

Wiley InterScience

Alimentary Pharmacology & Therapeutics

Volume 20 Issue 8, Pages 883 - 889

Published Online: 29 Sep 2004

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 123K) | Related Articles | Citation Tracking

Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis

T. O. G. Kovacs*, C. Q. Lee†, Y.-L. Chiu‡, B. L. Pilmer† & D. C. Metz§

*VA Greater Los Angeles Healthcare System, CURE Clinic, Los Angeles, CA, USA ; †TAP Pharmaceutical Products, Inc., Lake Forest, IL, USA ; ‡Abbott Laboratories, Abbott Park, IL, USA ; §University of Pennsylvania, Philadelphia, PA, USA

Correspondence to Dr T. O. G. Kovacs, Cure Digestive Diseases Research Center, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Building 115, Room 212, Los Angeles, CA 90073, USA.
E-mail: tkovacs@mednet.ucla.edu

Summary

Background: Some patients requiring acid suppression may be unable to take oral medications.

Aim: To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients.

Methods: The study included 87 Helicobacter pylori-negative patients with erosive oesophagitis. Each patient received 7 days of lansoprazole 30 mg orally prior to being randomized in a 3:1 fashion to intravenously lansoprazole 30 mg or intravenously placebo for 7 days. Basal acid output and pentagastrin-stimulated acid output were measured on days 8, 9 and 15.

Results: Median pentagastrin-stimulated acid output was 7.2 mmol/h after 7 days of oral lansoprazole. The median pentagastrin-stimulated acid output increased to 7.6 mmol/h after 7 days of intravenous lansoprazole compared with 26.9 mmol/h after intravenous placebo (P < 0.001).

Conclusions: Lansoprazole 30 mg administered intravenous was equivalent to the 30 mg oral capsule in gastric acid suppression. Intravenous proton pump inhibitor therapy represents an important treatment option for those with acid-related diseases who are unable to take oral medications.

Accepted for publication 21 July 2004

DIGITAL OBJECT IDENTIFIER (DOI)

10.1111/j.1365-2036.2004.02188.x About DOI